Unipolar Depression Clinical Trial
Official title:
The Effects of Sleep Deprivation on Antidepressant Response in Geriatric Depression: Neurometabolic Substrates Studied With PET
This study will use positron emission tomography (PET) to examine the effect of sleep deprivation on brain function.
This study seeks to better understand the effect of sleep deprivation (TSD) on brain
function using Positron Emission Tomography (PET). PET is an established research procedure
that produces images of the brain. The purpose of these images is to show changes in brain
activity associated with sleep deprivation. The neurochemical mechanisms underlying the TSD
acceleration of antidepressant efficacy have not been identified. An understanding of these
neurochemical processes may lead to the development of pharmacologic strategies that would
accelerate antidepressant response or more directly to the development of antidepressant
treatments that are more efficacious.
This study will be conducted in collaboration with Dr. Charles Reynolds' ongoing protocol
"Geriatric Depression: Neurobiology of Treatment" (IRB #970356). The impetus for the
clinical studies is the finding that the clinical response to antidepressant treatment in
geriatric depressed patients is delayed, with the median time to remission reported as up to
12 weeks. Thus, the development of a strategy to accelerate treatment response would
represent a substantial contribution to the treatment of geriatric depression. One approach
that has been reported to accelerate antidepressant response in mid-life depression is one
night of total sleep deprivation (TSD) prior to initiating antidepressant treatment. TSD has
also been shown to improve mood in depressed patients, the response to TSD may distinguish
subsequent treatment responders from non-responders and depressive relapse may occur after
naps or a night of recovery sleep. The neurochemical mechanisms underlying the TSD
acceleration of antidepressant efficacy have not been identified. An understanding of these
neurochemical processes may lead to the development of pharmacologic strategies that would
accelerate antidepressant response or more directly to the development of antidepressant
treatments that are more efficacious.
Advancements in brain imaging technology and radiotracer chemistry have made it possible to
measure metabolic activity and specific neurochemical mechanisms using Positron Emission
Tomography (PET). The proposed studies represent the initial step in characterizing the
neurochemical alterations produced by TSD and the impact of TSD on antidepressant response
by TSD in geriatric depressed patients using PET and a radiotracer for brain glucose
metabolism, [18F]-2deoxy-2-fluoro-D-glucose ([18F]-2DG). Having established the regional
metabolic alterations associated with sleep deprivation and recovery sleep in patients who
are subsequent treatment responders and compared the metabolic changes with treatment
non-responders, future studies will be undertaken using neuroreceptor radiotracers to define
the specific neurochemical pathways subserving the regional pattern of metabolic
alterations. The glucose metabolic response to sleep deprivation in mid-life depression has
been investigated at the UPMC PET Facility and at other institutions (e.g. Dube et al., in
preparation, Wu et al., 1991, 1992). The studies performed in the geriatric depressed
patients will be compared with the PET studies conducted in mid-life depressed patients to
assess the contribution of the aging process to the neurometabolic response to sleep.
For information on related studies, please follow these links:
http://clinicaltrials.gov/show/NCT00177294
http://clinicaltrials.gov/show/NCT00178035
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03256162 -
Ketamine as an Adjunctive Therapy for Major Depression
|
Phase 1 | |
Recruiting |
NCT05570110 -
Enoxolone in Major Depression - Biomarker-outcome Relationship
|
Phase 1/Phase 2 | |
Completed |
NCT02530164 -
Transcranial Direct Current Stimulation (tDCS) As Treatment for Major Depression
|
N/A | |
Completed |
NCT00964054 -
Depression Outcomes Study of Exercise
|
Phase 1 | |
Completed |
NCT01447602 -
A Clinical Trial of IPT-A to Prevent Suicide in Depressed Adolescents With Suicidal Behavior
|
Phase 3 | |
Completed |
NCT00517387 -
The Effects of Quetiapine XR on Cognition, Mood and Anxiety Symptoms in SSRI-Resistant Unipolar Depression
|
Phase 3 | |
Recruiting |
NCT04939649 -
Ketamine as an Adjunctive Therapy for Major Depression (2)
|
Phase 3 | |
Recruiting |
NCT05894980 -
How to Reduce Suicidal Thoughts and Impulsivity in Depression
|
N/A | |
Terminated |
NCT04712968 -
Efficacy of Daylight as Adjunctive Treatment in Patients With Depression
|
N/A | |
Enrolling by invitation |
NCT04717921 -
Assesment of Retinal Nerve Fiber Layer in First Episode Depressive Patients Using Selective Serotonin Reuptake Inhibitor
|
||
Recruiting |
NCT03358056 -
Effects of Mindfulness Based Cognitive Therapy on Emotional Processing
|
N/A | |
Recruiting |
NCT03711019 -
Efficacy of Convulsive Therapies During Continuation
|
N/A | |
Completed |
NCT02104232 -
Thinking Healthy Program - Peer Delivered, India (THPP-I)
|
N/A | |
Completed |
NCT02111915 -
Thinking Healthy Program - Peer Delivered (Pakistan)
|
N/A | |
Terminated |
NCT01219686 -
EScitalopram PIndolol ONset of Action
|
Phase 2/Phase 3 | |
Completed |
NCT00158990 -
Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression.
|
Phase 3 | |
Completed |
NCT01049347 -
Amitriptyline and Paroxetine Treatment of Major Depression
|
Phase 3 | |
Completed |
NCT03268434 -
Evaluation of Metacognitive Training for Depression (D-MCT) in Outpatient Care
|
N/A | |
Completed |
NCT01880957 -
PET and MRI Brain Imaging of Bipolar Disorder
|
N/A | |
Completed |
NCT04420793 -
Voice Changes During ECT
|